Does the renin-angiotensin system also regulate intra-ocular pressure?

Annals of Medicine

Volumn 40, Issue 6, 2008, Pages 418-427

  Vaajanen, Anu ^a   Luhtala, Satu ^b   Oksala, Olli ^a   Vapaatalo, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF JYVÄSKYLÄ   (Finland)

Author keywords

ACE; ACE inhibitors; ACE2; Ang (1 7); Ang (1 9); Angiotensin II; Eye; Glaucoma; Intra ocular pressure; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; CARBONATE DEHYDRATASE INHIBITOR; CATHEPSIN G; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AQUEOUS HUMOR; BIOSYNTHESIS; DRUG INHIBITION; ENZYME SYNTHESIS; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA; REVIEW; VITREOUS BODY;

ANIMALS; BIOSYNTHETIC PATHWAYS; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; WATER-ELECTROLYTE BALANCE;

EID: 50649094200     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890802043924     Document Type: Review

References (100)

1. Wu SY, Nemesure B, Leske MC. Observed versus indirect estimates of incidence of open-angle glaucoma. Am J Epidemiol. 2001;15;184-7.
2. Kroese M, Burton H, Vardy S, Rimmer T, McCarter D. Prevalence of primary open angle glaucoma in general ophthalmic practice in the United Kingdom. Br J Ophthalmol. 2002;86:978-80.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.
4. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-20.
5. Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-97.
6. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498-505.
7. Hirooka K, Baba T, Fujimura T, Shiraga F. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am J Ophthalmol. 2006;142:523-5.
8. Costagliola C, Verolino M, de Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of oral losartan potassium on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res. 2000;71:167-71.
9. Costagliola C, Di Benedetto R, De Caprio L, Verde R, Mastropasqua L. Effect of oral captopril (SQ 14225) on intraocular pressure in man. Eur J Ophthalmol. 1995;5:19-25.
10. Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2005;80:629-32.
11. Inoue T, Yokoyoma T, Mori Y, Sasaki Y, Hosokawa T, Yanagisawa H, et al. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. Curr Eye Res. 2001;23:133-8.
12. Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000;36:169-75.
13. Watkins RW, Baum T, Cedeno K, Smith EM, Yuen PH, Ahn HS, et al. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits. J Ocul Pharmacol. 1987;3:295-307.
14. Giardina WJ, Kleinert HD, Ebert DM, Wismer CT, Chekal MA, Stein HH. Intraocular pressure lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals. J Ocul Pharmacol. 1990;6:75-83.
15. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-13.
16. Jackson KE. Renin and Angiotensin. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill, Medical Publishing Division; 2001. p. 809-42.
17. Hall JE. Historical perspective of the renin-angiotensin system. Mol Biotechnol. 2003;24:27-39.
18. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Review Physiol Rev. 2006;86:747-803.
19. Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol. 2006;57:529-39.
20. Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong WF. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal, and pituitary of the rat. Proc Natl Acad Sci USA. 1986;83:7552-6.
21. Derkx FH, Alberda AT, Zeilmaker GH, Schalekamp MA. High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol. 1987;94:4-9.
22. Danser AHJ, Derkx FHM, Admiraal PJJ, Deinum J, de Jong PTVM, Schalekamp MADH. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994;35:1008-18.
23. Sramek SJ, Wallow IHL, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci. 1992;33:1627-32.
24. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996:80:159-63.
25. Savaskan E, Loffler KU, Meier F, Muller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res. 2004;36:312-20.
26. Van Haeringen NJ. The renin-angiotensin system in the human eye. Br J Ophthalmol. 1996;80:99-100.
27. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burcklé CA, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007;25:2441-53.
28. Su JB. Kinins and cardiovascular diseases. Curr Pharm Des. 2006;12:3423-35.
29. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JN, Brenner BM, editors. Hypertension: Pathophysiology, diagnosis and management. New York: Raven Press; 1990. p. 1287-311.
30. Buczko W, Matys T, Kucharewicz I, Chabielska E. The role of endothelium in antithrombotic effect of the reninangiotensin system blockade. J Physiol Pharmacol. 1999;50:499-507.
31. Al-Merani SA, Brooks DP, Chapman BJ, Munday KA. The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat. J Physiol. 1978;278:471-90.
32. Ruiz-Ortega M, Esteban V, Egido J. The regulation of the inflammatory response through nuclear factor-kappa b pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med. 2007;17:19-25.
33. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:1-9.
34. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24,11. Life Sci. 1993;52:1461-81.
35. Kucharewicz I, Pawlak R, Matys T, Chabielska E, Buczko W. Angiotensin-(1-7): an active member of the renin-angiotensin system. J Physiol Pharmacol. 2002;53:533-40.
36. Santos RAS, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000;91:45-62.
37. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-72.
38. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;8:8258-63.
39. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, et al. Angiotensin (1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol. 2005;289:2356-63.
40. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type I receptor. Circulation. 2005;111:1806-13.
41. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-8.
42. Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther. 1998;284:388-98.
43. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension. 1992;19:49-55.
44. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-70.
45. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Japan J Pharmacol. 1993;62:207-10.
46. Balcells E, Meng QC, Johnson WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol Heart Circ Physiol. 1997;273:1769-74.
47. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 1998;32:514-20.
48. Resende MM, Mill JG. Alternate angiotensin II-forming pathways and their importance in physiological or physiopathological conditions. Arq Bras Cardiol. 2002;78:432-8.
49. Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 2006;100:391-7.
50. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987;149:1186-92.
51. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-57.
52. Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev. 2006;14:187-93.
53. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14:1738-47.
54. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 2001;104:1274-9.
55. Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 2002;71:437-46.
56. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999;33:1399-405.
57. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem. 1982;257:15042-6.
58. Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem. 1982;257:8619-22.
59. Grisé C, Boucher R, Thibault G, Genest J. Formation of angiotensin II by tonin from partially purified human angiotensinogen. Can J Biochem. 1981;59:250-5.
60. Kokkonen JO, Saarinen J, Kovanen PT. Angiotensin II formation in the human heart: an ACE or non-ACE mediated pathway? Ann Med. 1998;309-13.
61. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-43.
62. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-43.
63. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension. 2003;41:871-3.
64. Brubaker RF. Clinical evaluation of circulation of aqueous humor flow. In: Tasman W, Jaeger EA, editors. Duane's Clinical Ophthalmology. Vol 3, Ch 46. Philadelphia: JB Lippincott Company; 1994. p. 1-11.
65. Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging. 1992;2:208-21.
66. Kardon RH, Weingeist TA. Anatomy of the ciliary body and outflow pathways. In: Tasman W, Jaeger EA, editors. Duane's Clinical Ophthalmology. Vol 3, Ch 43. Philadelphia: JB Lippincott Company; 1994. p. 1-26.
67. Weinreb RN. Uveoscleral outflow: the other outflow pathway. J Glauc. 2000;9:343-5.
68. Sramek SJ, Wallow IH, Day RP, Ehrlich EN. Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci. 1988;29:1749-52.
69. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res. 2004;29:419-27.
70. Shiota N, Saegusa Y, Nishimura K, Miyazaki M. Angiotensin II-generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Ther. 1997;24:243-8.
71. Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007;48:3301-11.
72. Schelling P, Ganten U, Sponer G, Unger T, Ganten D. Components of the renin angiotensin system in cerebrospinal fluid of rats and dogs with special consideration of the origin and fate of angiotensin II. Neuroendocrinology. 1980;31:297-308.
73. Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979;23;279-96.
74. Danser AH, van der Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989,68:160-7.
75. Geng L, Persson K, Nilsson SFE. Angiotensin converting enzyme (ACE) activity in porcine ocular tissue: effects of diet and ACE inhibitors. J Pharm Ther. 2003;19:589-96.
76. Ramirez M, Davidson EA, Luttenauer L, Elena P-P, Cumin F, Mathis GA, et al. The renin-angiotensin system in the rabbit eye. J Ocul Pharmacol Ther. 1996;12:299-312.
77. Culliane AB, Leung PS, Ortgo J, Coca-Prados M, Harvey BJ. Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br J Ophthalmol. 2002;86:676-83.
78. Lin C, Stone RA, Wax MB. Angiotensin binding sites in rabbit anterior uvea and human ciliary epithelial cells. Invest Ophthalmol Vis Sci. 1990;31:147-52.
79. 2+ and aldosterone production in bovine adrenal glomerulosa cells. J Biol Chem. 1984;259:8863-9.
80. Hou Y, Delamere NA. Influence of Ang II on cytoplasmic sodium in cultured rabbit nonpigmented ciliary epithelium. Am J Physiol Cell Physiol. 2002;283:552-9.
81. Langman MJS, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005;89:960-3.
82. Osusky R, Nussberger J, Amstutz C, Flammer J, Brunner HR. Individual measurements of angiotensin II concentrations in aqueous humor of the eye. Eur J Ophthalmol. 1994;4:228-33.
83. Reitsamer HA, Kiel JW. Relationship between ciliary body blood flow and aqueous production in rabbits. Invest Ophthalmol Vis Sci. 2003;44:3967-71.
84. Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. J Ocul Pharmacol. 1990;6:1-7.
85. Nilsson SF, Samuelsson M, Bill A, Stjernscantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707-16.
86. Weinreb RN, Toris CB, Gabelt BAT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47:53-64.
87. Haefliger IO, Flammer J, Luscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992;33:2340-3.
88. Yao K, Tschudi M, Flammer J, Luscher TF. Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. Invest Ophthalmol Vis Sci. 1991;32:1791-8.
89. Shen F, Zhang L, Liu T. Effects of angiotensin II on the 3H-TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells. Yan Ke Xue Bao. 2001;17:209-12 (in Chinese).
90. Inoue T, Yokoyoma T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Curr Eye Res. 2001;23:139-43.
91. Macri FJ. The action of angiotensin on intraocular pressure. Arch Ophthalmol. 1965;73:528-39.
92. Vaajanen A, Vapaatalo H, Kautiainen H, Oksala O. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci. 2008 Jan 25 (Epub ahead of print).
93. Bárány EH. Simultaneous measurement of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthalmol Vis Sci. 1964;3:135-43.
94. Vaajanen A, Mervaala E, Oksala O, Vapaatalo H. Is there a relationship between blood pressure and intraocular pressure? An experimental study in hypertensive rats. Curr Eye Res. 2008;33:325-32.
95. Konno T, Maruichi M, Takai S, Oku H, Sugiyama T, Uchibori T, et al. Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol. 2005;524:132-7.
96. Mabuchi F, Aihara M, Mackey MR, Lindsey JD, Weinreb RN. Regional optic nerve damage in experimental mouse glaucoma. Invest Ophthalmol Vis Sci. 2004;45:4352-8.
97. Sjølie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens. 2002;16:42-6.
98. Vita JB, Anderson JA, Hulem CD, Irving HL. Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci. 1981;20:255-7.
99. Weinreb RN, Sandman R, Ryder MI, Friberg TR. Angiotensin-converting enzyme activity in human aqueous humor. Arch Ophthalmol. 1985;103:34-6.
100. Maruichi M, Oku H, Takai S, Muramatsu M, Sugiyama T, Imamura Y, et al. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: A possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res. 2004;29:321-5.